A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. New technologies for manufacturing of biologics, which hold potential for the MENA biologics & biosimilars market growth.
Biologics are widely used to prevent, treat, diagnose or cure a variety of diseases such as cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.
Furthermore, Rapid reforms in the healthcare sector MENA region by government and multinational companies is expected to propel growth of the MENA biologics & biosimilars market. For Instance, In March 2020, The Ministry of Health (MOH) of Saudi Arabia signed a memorandum of understanding with Sanofi Saudi Arabia, to start localizing and transferring insulin industry technology locally in the Kingdom of Saudi Arabia and the possibility of external export to the GCC countries and the Middle East region
Market Dynamics
The MENA biologics & biosimilars market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of hemophilia. According to the World Federation Hemophilia Global Survey, there was approximately 5,050 people with hemophilia (PWH) in Egypt in 2013.
According to the Annual Global Survey, around 418 people were suffering from hemophilia in Saudi Arabia in 2016.
Moreover, increasing number of novel technology launches is expected to drive growth of the market.
For instance, In July 2018, Xbrane Biopharma AB (Xbrane) and STADA Arzneimittel AG (STADA) entered into a collaborative agreement for the development of Lucentis (ranibizumab) biosimilar for the treatment of several eye diseases mainly neovascular age-related macular degeneration, diabetic-related macular edema, and retinal vein occlusion, covering Europe, the U..S and some MENA and APAC markets.
Key features of the study:
- This report provides in-depth analysis of the MENA biologics & biosimilars market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) during the forecast period 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the MENA biologics & biosimilars market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological up gradation, market expansion, and marketing tactics
- The MENA biologics & biosimilars market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the MENA biologics & biosimilars market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- MENA Biologics & Biosimilars Market, By Product Type:
- Influenza Vaccines
- Factor VIII
- Xyntha
- Octanate
- Kovaltry
- Advate
- Koate
- Adynovate
- Kogenate
- Hemlibra
- Elocta
- Recombinate
- Feiba
- Immunate
- Alphanate
- Novoeight
- Erythropoietin
- Epoetin Alfa
- Binocrit
- Eprex
- Darbepoietin Alfa (Aranesp)
- Epoetin Alfa-epbx (Retacrit, Recormon)
- Aflibercept (EYLEA)
- Ziv-Aflibercept (ZALTRAP)
- MENA Biologics & Biosimilars Market, By Therapeutic Application:
- Hemophilia
- Age-related Macular Degeneration
- Kidney Diseases
- Influenza
- Others
- MENA Biologics & Biosimilars Market, By Region/ Country:
- Gulf
- By Country:
- By Product Type:
- Influenza Vaccines
- Factor VIII
- Xyntha
- Octanate
- Kovaltry
- Advate
- Koate
- Adynovate
- Kogenate
- Hemlibra
- Elocta
- Recombinate
- Feiba
- Immunate
- Alphanate
- Novoeight
- Erythropoietin
- Epoetin Alfa
- Binocrit
- Eprex
- Darbepoietin Alfa (Aranesp)
- Epoetin Alfa-epbx (Retacrit, Recormon)
- Aflibercept (EYLEA)
- Ziv-Aflibercept (ZALTRAP)
- By Therapeutic Application:
- Hemophilia
- Age-related Macular Degeneration
- Kidney Diseases
- Influenza
- Others
- Egypt
- By Product Type:
- Influenza Vaccines
- Factor VIII
- Xyntha
- Octanate
- Kovaltry
- Advate
- Koate
- Adynovate
- Kogenate
- Hemlibra
- Elocta
- Recombinate
- Feiba
- Immunate
- Alphanate
- Novoeight
- Erythropoietin
- Epoetin Alfa
- Binocrit
- Eprex
- Darbepoietin Alfa (Aranesp)
- Epoetin Alfa-epbx (Retacrit, Recormon)
- Aflibercept (EYLEA)
- Ziv-Aflibercept (ZALTRAP)
- By Therapeutic Application:
- Hemophilia
- Age-related Macular Degeneration
- Kidney Diseases
- Influenza
- Others
- Company Profiles
- Hoffmann-la Roche Ag
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
“*” marked represents similar segmentation in other categories in the respective section.
